(Q38130333)

29 August 2017

title

Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis (English)

1 reference

29 August 2017

John E Wolf

1

1 reference

29 August 2017

Darrell S Rigel

series ordinal

2

1 reference

29 August 2017

publication date

1 September 2013

1 reference

International Journal of Dermatology

29 August 2017

published in

1 reference

29 August 2017

volume

52

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

1063-1070

1 reference

Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis").

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Photodynamic therapy: is it a valuable treatment option for actinic keratoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Retrospective, descriptive, observational study of treatment of multiple actinic keratoses with topical methyl aminolevulinate and red light: results in clinical practice and correlation with fluorescence imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Adherence in dermatology: a review of the last 20 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2012.05776.X

10.1111/J.1365-4632.2012.05776.X

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference